TE-8105

TE-8105 is a GLP-1 receptor agonist that has demonstrated prolonged and potent efficacy in models of diabetes, obesity, and non-alcoholic steatohepatitis (NASH) [1].

12352209

GLP Receptor

GPCR/G Protein

Metabolic Disease

[H]N[C@@H](CC1=CN=CN1)C(NC(C)(C)C(N[C@H](C(NCC(N[C@H](C(N[C@@H](CC2=CC=CC=C2)C(N[C@H](C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@@H](C)C(N[C@@H](C)C(N[C@H](C(N[C@H](C(N[C@@H](CC4=CC=CC=C4)C(N[C@@H]([C@H](CC)C)C(N[C@@H](C)C(N[C@@H](CC5=CNC6=C5C=CC=C6)C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CC(C)C)=O)=O)=O)=O)=O)CCC(O)=O)=O)CCCCNC(CC[C@H](NC(CN7N=NC(CCC(NCCOCCOCCOCCOCCC(N[C@@H](C(NCCOCCOCCOCCOCCC(N[C@@H](C(O)=O)CCCCNC(CC[C@@H](NC(CCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)CCCCNC(CC[C@H](NC(CCCCCCCCCCCCCCC)=O)C(O)=O)=O)=O)=O)=C7)=O)C(O)=O)=O)=O)=O)=O)CCC(N)=O)=O)=O)CCC(O)=O)=O)CC(C)C)=O)=O)CO)=O)CO)=O)C(C)C)=O)=O)CO)=O)[C@@H](C)O)=O)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O)=O

C242H386N54O75

5251.97

[1]Wong MT, et al. 2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide. J Med Chem. 2025 Mar 27;68 (6) :6178-6192.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11042/

Peptides

No Development Reported